Welcome to our dedicated page for Artelo Biosciences SEC filings (Ticker: ARTL), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Wondering where Artelo Biosciences discloses the cash it burns on clinical trials or how often executives buy shares? You can stop hunting through EDGAR. This page gathers every Artelo Biosciences SEC filing—from the detailed annual report 10-K to fast 8-K material event notices—seconds after they post.
Start with the Artelo Biosciences quarterly earnings report 10-Q filing to see R&D spend and runway projections. Need drug-trial milestones or licensing updates? Our AI extracts them from each 8-K, then explains why they matter for a small-cap biotech. If you’re tracking leadership moves, real-time alerts flag Artelo Biosciences insider trading Form 4 transactions, letting you compare option exercises against upcoming data releases.
Stock Titan’s platform turns dense documents into plain language:
- AI-powered highlights that answer “understanding Artelo Biosciences SEC documents with AI”.
- Side-by-side trends across every Artelo Biosciences annual report 10-K simplified since IPO.
- Instant Form 4 dashboards for “Artelo Biosciences executive stock transactions Form 4”.
- Key tables pulled from the proxy statement so you can evaluate “Artelo Biosciences proxy statement executive compensation”.
Artelo Biosciences (Nasdaq: ARTL) entered into a securities purchase agreement on 24-Jun-2025 for a private placement of 136,843 common shares at $5.82 plus warrants covering 783,249 shares.
Gross proceeds: $1.425 million today, up to $6.403 million if all warrants are exercised. Instruments include pre-funded warrants (93,180 shares, $0.001 strike) and 5-year warrants at $5.82 (460,046 shares) and $10.00 (230,023 shares), all subject to 4.99%-9.99% ownership caps.
- Unit price: $6.195 per share and three warrants.
- Closing expected 26-Jun-2025.
- Company will file resale registration within 15 days.
- $250,000 of net proceeds earmarked to purchase SOL cryptocurrency; remainder for working capital.
The sale is exempt under Rule 506 of Regulation D; investors are accredited.
FAQ
What is the current stock price of Artelo Biosciences (ARTL)?
What is the market cap of Artelo Biosciences (ARTL)?
What is the primary focus of Artelo Biosciences?
What types of therapies is Artelo developing?
How does Artelo Biosciences differentiate itself in the biopharmaceutical industry?
Where is Artelo Biosciences headquartered?
What is the significance of the company’s proprietary cocrystal technology?
What conditions are targeted by Artelo’s FABP inhibitors?
How does Artelo Biosciences support its research and development efforts?
Is Artelo focused on addressing unmet medical needs?
